Halozyme Therapeutics, INC

Halozyme Therapeutics announced robust first-quarter 2026 financial results, driven by significant revenue growth, and initiated a new $1 billion share repurchase program.

Halozyme Therapeutics, Inc. reported on its Annual Meeting of Stockholders held on May 5, 2026, where key proposals including director elections and executive compensation were approved.

Halozyme Therapeutics announces the appointment of Darren Snellgrove as Chief Financial Officer, effective June 8, 2026, bringing extensive financial leadership experience from Johnson & Johnson.

Halozyme Therapeutics amended its bylaws to clarify director removal procedures and prohibit stockholder action without a meeting.

Halozyme Therapeutics, Inc. announced the appointment of David Ramsay, a former CFO, as its Interim Chief Financial Officer, effective March 23, 2026.

Halozyme Therapeutics announced raised financial guidance for 2026 and updated preliminary 2025 estimates, alongside the acquisition of Surf Bio for its hyperconcentration technology.

Halozyme Therapeutics reports robust Q3 2025 financial results driven by strong royalty growth and announces the strategic acquisition of Elektrofi, expanding its drug delivery technology portfolio.

Halozyme Therapeutics reports significant revenue and net income growth in Q2 2025, driven by increased royalties from ENHANZE partner product sales and strategic share repurchases.

Halozyme Therapeutics announces a successful first quarter in 2025, marked by significant revenue growth driven by increased royalties and product sales.

Halozyme Therapeutics' Q3 2024 results show significant revenue growth driven by royalties from its ENHANZE drug delivery technology and increased proprietary product sales.

Halozyme Therapeutics' Q2 2024 results show significant growth in royalties and proprietary product sales, contributing to a strong financial performance.

Halozyme Therapeutics reported a strong first quarter of 2024, driven by increased royalty revenues and advancements in its ENHANZE technology collaborations.

Halozyme Therapeutics' 2024 results showcase significant revenue growth fueled by ENHANZE royalties and strategic partnerships, alongside key regulatory approvals and pipeline advancements.

Halozyme Therapeutics' 2023 10-K filing highlights financial performance, strategic initiatives, and key risk factors, emphasizing growth through ENHANZE technology and auto-injector devices.

Halozyme Therapeutics President and CEO Helen Torley executed a series of stock transactions on July 8, 2026, including the exercise of stock options and the sale of common stock, all conducted under a pre-established Rule 10b5-1 trading plan.

Halozyme Therapeutics EVP David A. Ramsay reports transactions involving common stock, restricted stock units, and stock options.

Darren Snellgrove, SVP and CFO of Halozyme Therapeutics, has been granted restricted stock units and stock options, with specific vesting schedules outlined.

Halozyme Therapeutics Director Bernadette Connaughton has sold a total of 1,625 shares of common stock under a pre-arranged trading plan.

Halozyme Therapeutics director Mahesh Krishnan executed a 10b5-1 plan, acquiring 7,304 shares at $38.46 and selling 7,304 shares at $75.

Mark Howard Snyder, SVP and Chief Legal Officer of Halozyme Therapeutics, Inc., reported transactions involving common stock and restricted stock units.

Halozyme Therapeutics announces its 2026 Annual Meeting agenda, highlighting robust 2025 financial performance, strategic acquisitions, and significant partner advancements.

Halozyme Therapeutics has filed definitive additional materials related to its proxy statement with the Securities and Exchange Commission.

Halozyme Therapeutics will hold its 2025 Annual Meeting of Stockholders online on May 1, 2025, to elect directors, vote on executive compensation, and ratify the selection of its accounting firm.

Halozyme Therapeutics has filed definitive additional proxy materials with the SEC.

Halozyme Therapeutics is set to hold its 2024 Annual Meeting of Stockholders virtually on April 25, 2024, to vote on director elections, executive compensation, and corporate governance matters.

Vanguard Capital Management has reported beneficial ownership of 5.21% of Halozyme Therapeutics' common stock as of March 31, 2026.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 10.2% beneficial ownership stake in Halozyme Therapeutics, Inc. as of June 30, 2025.

State Street Corporation has reported a passive 4.9% beneficial ownership stake in Halozyme Therapeutics Inc., holding 6,053,007 shares of common stock as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, revealing a 13.1% beneficial ownership stake in Halozyme Therapeutics, Inc. as of March 31, 2025.